- Co-investment of all current institutional investors as well as several private investors and management

- Company now has access to over EUR 20 million in cash for the next phase of commercial and operational growth

Curetis AG today announced the closing of a Series B financing round totaling EUR 12.5 million. The financing was led by HBM Partners, which has taken a EUR 6.0 million equity stake in Curetis. Dr. Alexander Asam of HBM will join Curetis’ supervisory board.

In addition, the company’s existing institutional investors aeris Capital, LSP Life Sciences Partners, Forbion Capital, BioMedInvest, Roche Venture Fund, CD Venture and KfW have contributed a total of EUR 5.6 million to the round on a pro rata basis. Curetis’ management as well as several of the company’s founders, private investors and board members also co-invested.  » Read more...

- Company to host medical symposium on molecular antibiotic resistance testing in standard care

Curetis AG today announced the presentation of top-line clinical data from various European cohorts and performance evaluation studies of the Unyvero™ System and the Unyvero™ P50 pneumonia cartridge at the European Conference of Clinical Microbiology and Infectious Diseases (ECCMID) 2013 in Berlin. Data from the analysis of more than 1,000 patient samples and case reports will be presented in the poster session “Molecular diagnosis of bacterial pneumonia” on Monday, April 29, from 12:30-1:30pm.*  » Read more...

- AMPLIVANT™ TLR-ligand adjuvant to improve immunotherapies -

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, announces that Cornelis Melief, Professor at Leiden University and Chief Scientific Officer of ISA, presented details on the company’s novel AMPLIVANT™ technology at the American Association for Cancer Research (AACR) 2013 Annual Meeting. AMPLIVANT™ is based on a powerful, proprietary toll-like receptor (TLR) ligand designed to improve immunotherapies. This promotes direct dendritic cell targeting of the antigen as well as antigen processing, resulting in long-term activation of dendritic cells and antigen presentation.  » Read more...

InDex Pharmaceuticals today announced the completion of patient enrollment for its Phase III COLLECT study of Kappaproct. The multinational, randomized, double-blind, placebo-controlled study reached the recruitment goal of 120 patients with treatment-refractory Ulcerative Colitis (UC). InDex is expecting final study results in mid-2014.

The Phase III trial is designed to assess Kappaproct’s efficacy and safety in treatment-refractory UC patients. This cohort consists of chronic active UC patients who have failed all currently available pharmaceutical treatment and whose only remaining treatment option is surgical removal of the colon. This is a rare group of patients with a very high unmet medical need. Kappaproct has an Orphan Drug Designation in Europe.  » Read more...

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., will present details on the novel AMPLIVANT^TM platform at this year’s American Association for Cancer Research (AACR) Annual Meeting. AMPLIVANT^TM is based on a powerful, proprietary toll-like receptor (TLR) ligand improving immunotherapies.

Presentation title: “Synthetic vaccine for immunotherapy of high risk HPV infections“

Symposium: SY27 “New Cancer Vaccines“

Abstract number: SY27-01

Date: April 9, 2013, at 10:40 a.m.

Location: Room 202 at the Washington Convention Center.

The abstract is available at the AACR website www.aacr.org.